Document is current
Any future updates will be listed below
-
Authors
Luan, Chao https://orcid.org/0000-0001-8590-0953
Yang, Wen Lin https://orcid.org/0000-0002-8778-202X
Yin, Jia Wen https://orcid.org/0000-0002-3272-8480
Deng, Lie Hua https://orcid.org/0000-0001-9896-9685
Chen, Bin https://orcid.org/0000-0002-1114-7759
Liu, Hong Wei https://orcid.org/0009-0000-8562-1954
Zhang, Shou Min https://orcid.org/0009-0007-5344-9441
Han, Jian De https://orcid.org/0000-0002-4465-7632
Liu, Zhi Jun https://orcid.org/0009-0005-6672-8293
Dai, Xiang Rong https://orcid.org/0009-0001-9683-1444
Yin, Qiu Ju https://orcid.org/0000-0002-5203-3993
Yu, Xiao Hui https://orcid.org/0009-0007-0473-3542
Chen, Kun https://orcid.org/0000-0001-7501-4587
Gu, Heng https://orcid.org/0000-0002-3282-1626
Li, Benjamin Xiao Yi https://orcid.org/0000-0002-1453-4359
- License Information
-
More Information
Article History
Received: 21 July 2024
Accepted: 24 September 2024
First Online: 1 November 2024
Declarations
:
: Dr. Benjamin Xiao Yi Li is the Chairman & CEO of Zhaoke Ophthalmology Limited, and Director of Zhaoke Pharmaceutical (Hefei) Company Limited and Lee’s Pharmaceutical (Hong Kong) Limited. Xiang Rong DAI, and Xiao Hui YU are the staffs employed by Zhaoke Pharmaceutical (Hefei) Company Limited. Qiu Ju YIN is the staff employed by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited; The other authors declare no conflict of interest.
: The trial was conducted in accordance with the Good Clinical Practice guidelines and complies with the Declaration of Helsinki. The protocol and informed consent form were reviewed and approved by a properly constituted institutional review board/independent ethics committee/research ethics board before study commencement. The names of the approving ethics committees are listed in Supplementary Table .
